BERLIN.- The Pfizer-BioNTech vaccine protects against coronavirus for less than six months. The results of the most recent studies show that the dose is effective at 91.3% and over 95% that have been reported previously and are protected against South African variant.
Since he communicated these juveniles with companies, the injection was also 100% effective to prevent the disease between the participants of the assayo in South Africa, donde predominates a new variant called B1351, although the number of its participants was relatively low: 800.
One of the great occult fortunes of the world evaporated in one day
Estos son “los primary clinical results demonstrating that a vaccine can effectively protect against currently circulating variants“Essential factor for logging the group’s equipment and dealing with this pandemic for the global population”, explains Ugur Sahin, CEO and co-entrepreneur of BioNTech.
Pfizer and BioNTech have an estimated enero, a partir pruebas realized in vitro, which is an inferior era, a la observa frente a la cepa comun del virus, ‘la alta eficacia’ de la vacuna no parecía afectada frente a la variante sudafricana.
The data of the clinical trials corroborate these results, according to the press release of the Jews. Of the 46,307 participants in Phase 3 trials in various countries, the vaccine showed an efficacy of 91.3%, según la misma fuente. Of the 927 cases of covid-19 in the study, 850 cases concerned patients of the placebo group and 77 cases of the evacuation group. The Pfizer and BioNTech laboratories will be manufacturing 2500 million doses of their vaccine in 2021, one of the four approved in the European Union.
Agencies AFP and DPA